SCHEMBL526643

SCHEMBL526643

CCC(O)C[S+](C)[O-]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14593777 0.85
SCHEMBL12055898 0.79
SCHEMBL1847508 0.78
SCHEMBL6044442 0.76
SCHEMBL10406707 0.72 GPR84 (0.47)
SCHEMBL7435821 0.72 GPR84 (0.47)
SCHEMBL11504238 0.72 GPR84 (0.47)
SCHEMBL9439003 0.72 GPR84 (0.47)
SCHEMBL87376 0.71
SCHEMBL14593778 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118297-A1 POLYMORPHS OF DASATINIB AND PROCESS FOR PREPARATION THEREOF ASSIA CHEMICAL INDUSTRIES LTD. (IL) 2009-05-07 US claimed
US-11833249-B2 Rapidly disintegrating solid oral dosage forms containing dasatinib XSPRAY PHARMA AB (SE) 2023-12-05 US disclosed
US-11344500-B2 Rapidly disintegrating solid oral dosage forms containing dasatinib XSPRAY PHARMA AB (SE) 2022-05-31 US disclosed
US-20210085609-A1 RAPIDLY DISINTEGRATING SOLID ORAL DOSAGE FORMS CONTAINING DASATINIB XSPRAY PHARMA AB (SE) 2021-03-25 US disclosed
US-10894017-B1 Rapidly disintegrating solid oral dosage forms containing dasatinib XSPRAY PHARMA AB (SE) 2021-01-19 US disclosed
US-10894018-B1 Rapidly disintegrating solid oral dosage forms containing dasatinib XSPRAY PHARMA AB (SE) 2021-01-19 US disclosed
US-10874613-B1 Rapidly disintegrating solid oral dosage forms containing dasatinib XSPRAY PHARMA AB (SE) 2020-12-29 US disclosed
US-10874614-B1 Rapidly disintegrating solid oral dosage forms containing dasatinib XSPRAY PHARMA AB (SE) 2020-12-29 US disclosed
US-10869836-B1 Rapidly disintegrating solid oral dosage forms containing dasatinib XSPRAY PHARMA AB (SE) 2020-12-22 US disclosed
US-10869837-B1 Rapidly disintegrating solid oral dosage forms containing dasatinib XSPRAY PHARMA AB (SE) 2020-12-22 US disclosed
EP-2598147-A1 N-METHYLFORMAMIDE SOLVATE OF DASATINIB Ranbaxy Laboratories Limited (IN) 2013-06-05 EP disclosed
EP-2537847-A1 Polymorphs of dasatinib and process for preparation thereof TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) 2012-12-26 EP disclosed
EP-2508523-A2 Polymorphs of dasatinib and process for preparation thereof Teva Pharmaceutical Industries Ltd. (IL) 2012-10-10 EP disclosed
WO-2012014149-A1 N-METHYLFORMAMIDE SOLVATE OF DASATINIB RANBAXY LABORATORIES LIMITED (IN) 2012-02-02 WO disclosed
US-8067423-B2 Polymorphs of dasatinib isopropyl alcohol and process for preparation thereof TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2011-11-29 US disclosed
US-7973045-B2 Anhydrous form of dasatinib and process for preparation thereof TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2011-07-05 US disclosed
US-20100256158-A1 POLYMORPHS OF DASATINIB AND PROCESS FOR PREPARATION THEREOF ASSIA CHEMICAL INDUSTRIES LTD. (IL) 2010-10-07 US disclosed
EP-2207777-A2 POLYMORPHS OF DASATINIB AND PROCESS FOR PREPARATION THEREOF Teva Pharmaceutical Industries Ltd. (IL) 2010-07-21 EP disclosed
US-20090118297-A1 POLYMORPHS OF DASATINIB AND PROCESS FOR PREPARATION THEREOF ASSIA CHEMICAL INDUSTRIES LTD. (IL) 2009-05-07 US disclosed
WO-2009053854-A2 POLYMORPHS OF DASATINIB AND PROCESS FOR PREPARATION THEREOF TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) 2009-04-30 WO disclosed